ScinoPharm and Foresee Pharmaceuticals to form drug development JV

ScinoPharm (Tainan, Taiwan) and Foresee Pharmaceuticals (Newark, DE) have signed a joint venture agreement under which they will develop injectable peptide drugs, starting with a Leuprolide oncological drug, the companies say. The jv involves a $3.6-million investment from ScinoPharm, and will develop a treatment for prostate cancer. Other details of the jv agreement have not been disclosed.   The new drug will be in the Phase III clinical trial in the United States by late 2013, the companies say. If the drug is approved by US authorities, it will be...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers